Identification of Tumor Antigen in the Breast Cancer Vaccine
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The tumor antigen in the breast cancer vaccine which activated the anti-tumor immunity response was determined according to the antigen-specific antibodies existent in the serum of the immunized mice by immunoproteomics analysis. The results showed that the antibody titer of immunized mice serum was over 6400 and the high antibody titer suggested that the humoral immunity on anticancer was strengthened. SDS-PAGE and western-blot analysis showed that the protein extracted from Ca761 cells treated with cartilage polysaccharide was bonded with the immune serum at an estimated molecular mass of 50 kDa. 2D-PAGE and western-blot analysis showed that the tumor antigens activated anti-tumor immune response were acidic protein at 50 kDa. By MALDI-TOF-MS, the reactive protein was identified as α-tubulin. In summary, structure and expression of tumor antigen (α-tubulin) in Ca761 cells was modified with the cartilage polysaccharide treatment, therefore, the anti-tumor immunity of mice was activated by the tumor vaccine so that the mice immunized with the tumor vaccine could prevent from invasion of tumor cells. The immunogenic of α-tubulin was strengthened after the treatment with cartilage polysaccharide, which could be developed as a new vaccine.
